Identification and validation of a small molecule targeting ROR1 for the treatment of triple negative breast cancer

Introduction: Breast cancer is the most common cancer in women, with roughly 10–15% of new cases classified as triple-negative breast cancer (TNBC). Traditional chemotherapies are often toxic to normal cells. Therefore, it is important to discover new anticancer compounds that target TNBC while caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Shradheya R. R., Ta, Tram M., Khan, Maryam, Singh, Archana, Singh, Indrakant K., Peethambaran, Bela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534069/
https://www.ncbi.nlm.nih.gov/pubmed/37779899
http://dx.doi.org/10.3389/fcell.2023.1243763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534069/
https://www.ncbi.nlm.nih.gov/pubmed/37779899
http://dx.doi.org/10.3389/fcell.2023.1243763

Ejemplares similares